Welcome to Holly Springs, North Carolina— home to Roche/Genentech's largest-ever investment: a $2B greenfield start-up where next-generation technology, high-performing teams and Operational Excellence converge to create the global standard for high-volume, highly-efficient Drug Product manufacturing.

The facility's core is defined by Innovation - leveraging advanced automation, robotics, digital tools, real-time data analytics, and simple, streamlined processes to produce the highest quality medicines. This plant meets today’s demand for CVRM (Cardiovascular, Renal, and Metabolism) medicines and is scalable to grow with the portfolio, which focuses on next-generation metabolic medicines specifically targeting the global obesity epidemic and Type 2 diabetes. This is a fast-paced, entrepreneurial environment with a high-level of accountability, with planned launch in 2028.

Are you a problem-solver and change-agent who thrives in a Team environment, eager to tackle the most complex manufacturing challenges? If so, this is a once-in-a-lifetime opportunity to launch a state-of-the-art facility from the ground-up and shape the culture of our organization for the next generation.

Join us in Holly Springs, where you won't just build a plant—you will build the future of medicine.

The Opportunity

The Senior Manager Business Intelligence, AI & Data Governance is the site's technical and strategic leader for data-driven operations, responsible for designing, building, and maintaining a comprehensive data ecosystem that drives actionable intelligence across manufacturing, quality, and warehouse operations. This is a working specialist role—you will design and build dashboards, collaborate on data analysis, and establish data governance norms across the site, while simultaneously leading and mentoring a high-performing team of data engineers, BI developers, data scientists, and data governance specialists. You bridge complex engineering and data architectures with daily manufacturing, quality, and warehouse operations, ensuring intelligence is actively utilized, continuously validated, and expanded to deliver measurable business impact.

What You’ll Do

1. Enterprise BI Strategy & Technical Delivery

● Design, deploy, and personally build site-wide BI dashboards, analytics pipelines, and KPI frameworks that support operational, quality, and executive decision-making ● Analyze plant data to proactively identify operational opportunities (yield optimization, cycle time reduction, energy efficiency, quality improvements) and partner with business functions to translate insights into action

● Co-design data visuals and analytics solutions with Operations, Quality, Engineering, and Warehouse teams, ensuring relevance and usability

● Establish and manage analytics time-to-insight standards, reducing lead time for operational reports and batch disposition analytics

2. Artificial Intelligence & Predictive Analytics

● Lead the execution of AI/ML initiatives including predictive maintenance, yield optimization, and real-time operator decision support

● Drive measurable improvements in batch yield, equipment uptime (OEE), or downtime reduction through predictive AI models

● Ensure AI model validation and governance align with GxP requirements

3. Data Governance & GxP Compliance Leadership

● Establish and enforce site-wide data governance policies, data lineage protocols, and data quality assurance mechanisms for all non-ERP data sources (SCADA, MES, LIMS, historian systems, IoT platforms)

● Ensure compliance with FDA 21 CFR Part 11 and ALCOA+ principles across data operations

● Lead data quality assurance mechanisms and maintain 100% adherence to GxP/ALCOA+ standards

● Partner with Quality Assurance and Compliance teams to align data integrity protocols and AI validation strategies

● Establish data governance norms for the site, defining standards for data collection, storage, access, and usage

4. Data Architecture & Integration

● Partner with IT/OT teams to design and oversee integration of data pipelines across SCADA, MES, LIMS, and ERP systems into a unified analytics data layer ● Collaborate on architectural decisions that ensure scalability, security, and regulatory compliance

● Monitor data integration completeness and drive continuous improvement in system connectivity

5. Team Leadership & Development

● Build, mentor, and lead a high-performing team of data engineers, BI developers, data scientists, and data governance specialists

● Foster a culture of technical excellence, continuous learning, and cross-functional collaboration

● Provide hands-on technical mentoring and code reviews; model best practices in design, analysis, and execution

● Develop team members' technical and leadership capabilities through coaching and growth opportunities

6. Value Tracking & Business Growth

● Establish clear KPIs to quantify business value across BI, AI, and Digital Twin initiatives (e.g., reduction in batch cycle time, lower deviation rates, reduced energy consumption, improved OEE)

● Regularly report metrics and ROI to site leadership

● Proactively scout new manufacturing use cases, ROI opportunities, and continuous improvement projects to expand the Digital Twin's footprint and analytics capabilities

Who You Are

● B.S. or M.S. in Chemical Engineering, Mechanical Engineering, Data Science, Computer Science, Industrial Automation, or a related technical field

● 8+ years of experience in pharmaceutical manufacturing, process engineering, automation, data analytics, or industrial digital transformation

● Proven hands-on experience designing and building BI dashboards, analytics solutions, and data pipelines (SQL, Python/R, or equivalent)

● Hands-on experience with simulation, Digital Twin solutions, or advanced data modeling—demonstrating ability to drive insights and operational improvements ● Deep understanding of pharma plant operations (GMP, batch process control, PAT) paired with familiarity in data architectures (IoT, MES, SCADA, historian systems, simulation software like AspenTech, Ansys, or Siemens)

Product & Program Management:

● Proven track record in managing product lifecycles, backlogs, and use case prioritization with demonstrated ability to translate complex business requirements into prioritized, actionable deliverables

● Strong background in building business cases and demonstrating value realization through data-driven metrics

Data Governance & Compliance:

● Experience establishing and enforcing data governance policies, data lineage, and quality assurance mechanisms in GxP-regulated environments

● Demonstrated expertise in FDA 21 CFR Part 11 and ALCOA+ compliance ● Experience leading data governance initiatives outside of ERP systems

Leadership & Stakeholder Management:

● Demonstrated success in cross-functional stakeholder management, effectively bridging communication between technical teams, operations, engineering, and quality functions ● Ability to lead, mentor, and develop high-performing technical teams

● Experience driving organizational adoption of new technologies and methodologies Certifications (Preferred):

● Agile/Scrum Product Owner (CSPO/PSPO)

● Lean Six Sigma (Green or Black Belt)

● Project Management Professional (PMP)

● GxP/ALCOA+ compliance certification or training

Relocation assistance is available for this role.

The expected salary range for this position based on the primary location for this position of Holly Springs, North Carolina is $133,400 - $247,800. Actual pay will be determined based on experience, level, qualifications, geographic location, and other job-related factors permitted by law. A discretionary annual bonus may be available based on individual and Company performance.

Link to Benefits

Genentech is an equal opportunity employer. It is our policy and practice to employ, promote, and otherwise treat any and all employees and applicants on the basis of merit, qualifications, and competence. The company's policy prohibits unlawful discrimination, including but not limited to, discrimination on the basis of Protected Veteran status, individuals with disabilities status, and consistent with all federal, state, or local laws.

If you have a disability and need an accommodation in relation to the online application process, please contact us by completing this form Accommodations for Applicants.

About the company

Genentech is a biotechnology company focused on researching and developing medicines and therapies to address unmet medical needs. It uses large-scale R&D, with about 13,500 employees and 40 approved medicines; it develops biologics and other therapies marketed through healthcare providers, generating revenue from sales. It differentiates itself with a large patent portfolio (around 20,000 patents) and multiple FDA Breakthrough Therapy Designations, along with a patient-centric approach that weighs access and affordability. Its goal is to advance medical science and deliver high-quality, effective therapies that improve patient health and support the broader medical community.

Company Size

10,001+

Company Stage

Grant

Total Funding

$47.8M

Headquarters

San Francisco, California

Founded

1976

Get referred to Genentech

See people who can refer or advise you

Simplify's Take

What believers are saying

Hillsboro broke ground September 28, 2026 on a $750 million device fill-finish plant.
The project adds 250 jobs and strengthens U.S. supply for oncology, neurology, immunology.
Roche opened Boston's CVRM Innovation Center on September 17, 2026, expanding discovery capacity.

What critics are saying

September 2026 layoffs cut 265 South San Francisco jobs, ending a 40-year plant.
June and July 2026 cuts removed 103 gRED roles, signaling continuing research retrenchment.
Vabysmo concentration leaves Genentech vulnerable to a retinal franchise reversal by 2027.

What makes Genentech unique

Roche-backed Genentech pairs drug discovery with manufacturing, diagnostics, and global commercialization at scale.
Vabysmo delivered real-world eye-disease data on September 30, 2026 across 28 countries.
The September 24, 2026 Earendil deal shows Genentech still commands elite biotech partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus
Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

-3%

2 year growth

-3%

Associated Press

Oct 16th, 2026

FDA approves Genentech's Enspryng as first at-home injection for thyroid eye disease

Genentech, a member of the Roche Group, said the US Food and Drug Administration (FDA) has approved Enspryng for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and patients or caregivers can give it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis response, against 23.4% on placebo. Diplopia fell in 60.7% versus 25.8%. The sister trial, SatraGO-1, missed its primary endpoint at week 24. No new safety signals emerged. The approval, which followed a priority review, is Enspryng's second indication after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for MOGAD, with a decision expected in January 2027.

The Hindu BusinessLine

Oct 14th, 2026

Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo.

Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo. By PTI. Updated - October 14, 2026 at 02:43 PM. Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement resolves all pending disputes between the two companies across multiple jurisdictions, including the US and Canada, the biopharmaceutical company said in a regulatory filing on Wednesday. Under the terms of the agreement, Biocon is cleared to launch Pebrilzo in the European Union and the United Kingdom in the first quarter of calendar year (CY) 2027, followed by a launch in the US in the third quarter of CY 2028. For other rest of the world markets, the launch is slated for 2026-2028, or earlier under certain circumstances. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

PR Newswire

Oct 13th, 2026

2026 Patient Innovators Awards winners announced at Courier Health's annual Summit.

2026 Patient Innovators Awards winners announced at Courier Health's annual Summit. Oct 13, 2026, 09:00 ET Honorees celebrated as biopharma gathered in New York City to chart the future of the patient experience NEW YORK, Oct. 13, 2026 /PRNewswire/ - Courier Health, the leading technology company for managing patient experiences, today announced the winners of the second annual Patient Innovators Awards, which recognize the biopharma teams and leaders going above and beyond to improve patient access, innovation, and overall outcomes. Winners were announced live on October 6th at the third annual Patient Innovators Summit in New York City. The invite-only event brought together Patient Services, Access & Reimbursement, and Commercial IT & Analytics leaders from more than 75 biopharma companies. Together, attendees represented more than 100 disease states and roughly 35 million patients with previously unmet needs. Four teams and one individual were recognized for driving innovation and measurably improving the patient experience: * Rare Disease Champions of the Year: KalVista, a Company of Chiesi Group * Patient Services Team of the Year: Priovant Therapeutics * Field Access Team of the Year: UCB, Inc. * Patient Champion of the Year: Rob Chuba, Alkermes * Patient Innovators of the Year: Bristol Myers Squibb's CAR T-cell therapy Patient Access Support Services (PASS) team "Being named Patient Services Team of the Year is a testament to the team and program we're building," said Lee Liberator, Vice President of Patient Services and Reimbursement at Priovant Therapeutics. "We've built a unique program centered around what patients actually need from us, and we're proud to be recognized for our commitment to innovating and championing a better patient experience." In his opening keynote, Danny Sigurdson, Founder and CEO of Courier Health, described the moment as a fork in the road. As manufacturers take greater internal control of their programs, data ownership, outcomes-based measurement, and AI-enabled workflow innovation have become critical. Organizations that invest in the right foundation will gain greater operational leverage to focus on their core competency - supporting patients and providers - while those that don't will fall further behind. "This year's Patient Innovators Awards winners are proof that a better path, and a brighter future, is already being built," said Danny Sigurdson. "These teams and our individual Patient Champion of the Year aren't afraid to challenge the status quo and rethink how their programs run. They never lose sight of the patient, and it's an honor to recognize their contributions." This year's Patient Innovators Summit featured 11 industry speakers from companies including Alkermes, Beren Therapeutics, Corcept Therapeutics, Compass Pathways, Dyne Therapeutics, Genentech, and Tarus Pharmaceuticals. The audience also heard a powerful firsthand story from Mark Dant, rare disease advocate and Volunteer Executive Director for the Ryan Foundation. About Courier Health Courier Health is a New York City-based technology company on a mission to improve the patient experience for hundreds of millions of people living with a chronic condition or rare disease. The company develops and delivers the fastest-growing patient experience solution for the life sciences industry. Companies that choose Courier Health are achieving double-digit improvements to patient starts, time-to-start and ongoing adherence to life-altering therapies. As host of the invite-only Patient Innovators Summit and publisher of The State of Patient-Centricity in Biopharma report, Courier Health is backed by leading investors, including Oak HC/FT, Norwest and Work-Bench. Follow Courier Health on LinkedIn and learn more at www.courierhealth.com. SOURCE Courier Health

Yahoo Finance

Oct 9th, 2026

FDA approves Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The FDA has approved Genentech's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth indication in the US. The approval follows results from the Phase III ATOMIC study, published in The New England Journal of Medicine. The trial showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival was 86% with Tecentriq combined with mFOLFOX6, versus 76% with mFOLFOX6 alone. Nearly 25% of colon cancers are diagnosed at stage III. Almost one in three patients with stage III colon cancer experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population.

Pharma Journalist

Oct 7th, 2026

Alector licenses Parkinson's drug program to Genentech for $1.27B.

Alector licenses Parkinson's drug program to Genentech for $1.27B. On Oct 7, 2026 Alector has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize AL050, an investigational therapy designed to treat a key cause of neurodegeneration linked to Parkinson's disease. Under the agreement, Genentech will receive worldwide rights to AL050, which is designed to address deficiencies in glucocerebrosidase (GCase), an enzyme linked to Parkinson's disease, particularly in people carrying mutations in the GBA1 gene. Alector will receive $100 million upfront from Genentech and could receive up to an additional $1.17 billion in development, regulatory and commercial milestone payments. The company will also be eligible for tiered royalties based on net sales. AL050 combines an engineered version of the GCase enzyme with Alector's proprietary Alector Brain Carrier (ABC) technology. The approach is designed to help the therapy cross the blood-brain barrier and reach the brain, where GCase deficiency can cause harmful lipids to build up in nerve cells. The therapy is intended to break down glucosylsphingosine and glucosylceramide, two lipids that can accumulate when GCase activity is reduced. Alector believes reducing this buildup could help improve cell function and potentially slow the progression of Parkinson's disease. GCase deficiency is increasingly being studied as an important driver of Parkinson's disease. People with GBA1 mutations are at higher risk of developing the disease, although GCase-related mechanisms may also play a role in patients without these mutations. Under the partnership, Genentech will take responsibility for the development, regulatory work, manufacturing and commercialization of AL050 across all potential indications. Alector will retain ownership of its ABC technology and continue using the platform in its wholly owned pipeline. Alector CEO Arnon Rosenthal said the company designed AL050 to address two major challenges in treating GCase deficiency: developing an enzyme with strong and lasting activity and delivering it effectively into the brain. The deal also gives Alector additional resources to advance its other programs. The company said the partnership extends its cash runway into 2029. Alector plans to use these resources to advance its subcutaneously delivered, brain-enabled anti-Aβ antibody program toward multi-cohort clinical data in Alzheimer's disease. The company also plans to move its brain-enabled tau siRNA and alpha-synuclein siRNA programs through IND-enabling studies and toward regulatory filings. The collaboration marks another major step in Genentech's efforts to develop new treatments for Parkinson's disease, while giving Alector the financial support to continue developing therapies targeting neurodegenerative diseases.

Genentech

Senior Manager Business Intelligence - AI & Data Governance, CVRM

About the job